AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
Back to search results

The Usage of Oblongifolin C, a Natural Compound from Garcinia yunnanensis Hu, on Treating High Metastatic Cancer

Summary
Yhe present invention to provide a compound, Oblongifolin C, a natural compund isolated from Garcinia yunnanensis Hu, for its effects of anti-migration and anti-invasion against esophageal cancer and its use as anticancer drug against esophageal cancer.
Technology Benefits
In this invention, we found that Oblongifolin C, a natural compound from Garcinia yunnanensis Hu, can inhibit the migration and invasion of esophageal cancer.
Technology Application
Oblongifolin C can be developed as anticancer drug against esophageal cancer.
Detailed Technology Description
We have screened various components using different cancer cells, and found that several polyprenylated acylphloroglucinol (PPAP) compounds had potent cytotoxic effects on human colorectal cancer cell lines without affecting the normal human colon fibroblasts. In this invention, we found that Oblongifolin C can significantly inhibit esophageal cancer cell (ESCC) ECA109 migration and invasion. Thus, Oblongifolin C can be developed as anticancer drug against esophageal cancer.
Supplementary Information
Inventor: DRANOFF, Glenn | VANNEMAN, Matthew | FREEMAN, Gordon
Priority Number: WO2010080124A9
IPC Current: A61K003816 | A61P003500
Assignee Applicant: Dana-Farber Cancer Institute Inc.
Title: NKG2D-FC FOR IMMUNOTHERAPY | NKG2D-FC POUR IMMUNOTHÉRAPIE
Usefulness: NKG2D-FC FOR IMMUNOTHERAPY | NKG2D-FC POUR IMMUNOTHÉRAPIE
Summary: The method is useful for treating cancer including melanoma, lung cancer, plasma cell cancer, leukemia, lymphoma, ovarian cancer, colon cancer, pancreatic cancer and prostate cancer in subjects (claimed) e.g. humans.
Novelty: Treating cancer e.g. melanoma, lung cancer and leukemia in subject e.g. human having NKGD ligand expressing cancer, involves administering composition comprising NKG2D-Fc chimera, and carrier to subject
Industry
Disease Diagnostic/Treatment
Sub Category
Cancer/Tumor
Application Date
2013.01.10
Application No.
US 61/750,870
Others
Filed
ID No.
A61/BZ/Oblo/US0P
Country/Region
Hong Kong

For more information, please click Here
Mobile Device